These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 5578236

  • 41. Brain-death-induced cardiac contractile dysfunction: studies of possible neurohormonal and blood-borne mediators.
    Galiñanes M, Hearse DJ.
    J Mol Cell Cardiol; 1994 Apr; 26(4):481-98. PubMed ID: 7915333
    [Abstract] [Full Text] [Related]

  • 42. Quinolinic acid: effects on brain catecholamine and c-AMP content during L-dopa and reserpine administration.
    Beskid M, Finkiewicz-Murawiejska L.
    Exp Toxicol Pathol; 1992 Apr; 44(2):66-9. PubMed ID: 1319782
    [Abstract] [Full Text] [Related]

  • 43. Effect of decarboxylase inhibition and neuroleptic drugs on the DOPA level in rat brain.
    Cegrell L, Nordgren L, Rosengren AM.
    Res Commun Chem Pathol Pharmacol; 1970 Jul; 1(4):479-84. PubMed ID: 4400174
    [No Abstract] [Full Text] [Related]

  • 44. [Pharmacology of several aromatic amino acid decarboxylase inhibitors].
    Uspenskiĭ AE, Dabagov NS, Skoldinov AP.
    Biull Eksp Biol Med; 1978 Oct; 86(10):444-7. PubMed ID: 309344
    [Abstract] [Full Text] [Related]

  • 45. Role of peripheral adrenoreceptors and vasopressin in the suppression of plasma renin activity by L-dopa in carbidopa-treated dogs.
    Blair ML, Reid IA, Keil LC, Ganong WF.
    J Pharmacol Exp Ther; 1979 Sep; 210(3):368-72. PubMed ID: 480187
    [Abstract] [Full Text] [Related]

  • 46. Transfer of DOPA from the sympatho-adrenal system to the pancreas, liver and kidney via the blood circulation.
    Andén NE, Grabowska-Andén M, Schwieler J.
    Acta Physiol Scand; 1989 May; 136(1):75-9. PubMed ID: 2570506
    [Abstract] [Full Text] [Related]

  • 47. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H, Ullberg S.
    Arch Int Pharmacodyn Ther; 1972 Oct; 199(2):376-88. PubMed ID: 4627124
    [No Abstract] [Full Text] [Related]

  • 48. [Relationship between the antihypertensive activity of methyldopa and the appearance of its metabolites in the heart and brain of the hypertensive rat].
    Cohen Y, Wepierre J, Jacquot C, Rapin J.
    Arch Int Pharmacodyn Ther; 1974 Feb; 207(2):348-60. PubMed ID: 4827419
    [No Abstract] [Full Text] [Related]

  • 49. An analysis of the peripheral effects of l-DOPA on autonomic nerve function.
    Antonaccio MJ, Robson RD.
    Br J Pharmacol; 1974 Sep; 52(1):41-50. PubMed ID: 4451808
    [Abstract] [Full Text] [Related]

  • 50. The cardiovascular effects of L-dopa in the pithed rat.
    Eden E, Nasmyth PA.
    Br J Pharmacol; 1974 Aug; 51(4):473-80. PubMed ID: 4451761
    [Abstract] [Full Text] [Related]

  • 51. [Correction of arterial pressure in rats with hereditary hypertension by altering catecholamine metabolism in early ontogeny].
    Naumenko EV, Maslova LN, Markel' AL, Gordienko NI.
    Biull Eksp Biol Med; 1987 Oct; 104(10):464-6. PubMed ID: 3676471
    [Abstract] [Full Text] [Related]

  • 52. The depression of sensitivity to noradrenaline caused by L-dopa.
    Eden E, Nasmyth PA.
    J Physiol; 1973 Apr; 230(1):7P-8P. PubMed ID: 4702454
    [No Abstract] [Full Text] [Related]

  • 53. Modification of the cardiovascular effects of L-dopa in anesthetized dogs by inhibitors of enzymes involved in catecholamine metabolism.
    Robson RD.
    Circ Res; 1971 Jun; 28(6):662-70. PubMed ID: 4325846
    [No Abstract] [Full Text] [Related]

  • 54. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS, Hsu TH, Bianchine JR.
    J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
    [Abstract] [Full Text] [Related]

  • 55. Inhibition of DOPA accumulation by rat brain at critical L-DOPA circulating concentrations.
    Horst WD, Bautz G, Renyi E, Spirt N.
    Adv Neurol; 1974 Feb; 5():369-73. PubMed ID: 4440584
    [No Abstract] [Full Text] [Related]

  • 56. Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs.
    Lovinger R, Holland J, Kaplan S, Grumbach M, Boryczka AT, Shackelford R, Salmon J, Reid IA, Ganong WF.
    Neuroscience; 1976 Dec; 1(6):443-50. PubMed ID: 11370235
    [Abstract] [Full Text] [Related]

  • 57. [Inhibitors of catecholamine biosynthesis (review of the literature)].
    Frantsuzova SB.
    Farmakol Toksikol; 1973 Dec; 36(5):624-8. PubMed ID: 4150865
    [No Abstract] [Full Text] [Related]

  • 58. Tissue catecholamine and arterial blood pressure changes in non-anaesthetised rats following administration of a new derivative of furanocarboxylic acid with pressor effect.
    Filczewski M, Szymańska-Kosmala M.
    Acta Physiol Pol; 1978 Dec; 29(3):251-8. PubMed ID: 707143
    [Abstract] [Full Text] [Related]

  • 59. [On the formation of H-3-dopa from H-3-tyrosine and determination of the dopa synthesis rate in the fowl and cat adrenal gland under in vivo conditions].
    Hempel K, Männl HF.
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967 Dec; 257(4):391-408. PubMed ID: 4232726
    [No Abstract] [Full Text] [Related]

  • 60. Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs.
    Furuta Y, Hashimoto K, Iwatsuki K, Takeuchi O.
    Br J Pharmacol; 1973 Jan; 47(1):77-84. PubMed ID: 4717022
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.